1. Assessment of the population coverage of an HIV-1 vaccine targeting sequences surrounding the viral protease cleavage sites in Gag, Pol, or all 12 protease cleavage sites
- Author
-
Ma Luo, Binhua Liang, and Mathew Daniel
- Subjects
medicine.medical_treatment ,T cell ,030231 tropical medicine ,Population ,Epitopes, T-Lymphocyte ,HIV Infections ,Computational biology ,Human leukocyte antigen ,Biology ,gag Gene Products, Human Immunodeficiency Virus ,Epitope ,03 medical and health sciences ,0302 clinical medicine ,Immune Epitope Database and Analysis Resource ,medicine ,Humans ,Cytotoxic T cell ,030212 general & internal medicine ,Allele ,education ,AIDS Vaccines ,education.field_of_study ,Protease ,General Veterinary ,General Immunology and Microbiology ,Public Health, Environmental and Occupational Health ,Infectious Diseases ,medicine.anatomical_structure ,HIV-1 ,Molecular Medicine ,Peptide Hydrolases - Abstract
Development of an effective HIV-1 vaccine has been a great challenge faced by the research community. Recently a novel strategy targeting the viral protease cleavage sites (PCSs) has been tested and shown promising results. This T cell-based vaccine strategy depends on individuals expressing certain HLA class I molecules and since each population has unique distributions of HLA class I alleles, population coverage analysis is required to assess feasibility. Utilizing the validated CD8 T cell epitope data from previous studies we conducted coverage analysis of an HIV-1 vaccine targeting the sequences surrounding all 12-PCSs, Gag-PCSs, and Pol-PCSs. The population coverage, average epitope hit, and minimum number of epitopes recognized by 90% of the population (PC90) was compiled for 66 countries and 16 geographical regions using the web tool provided by “Immune Epitope Database and Analysis Resource”. Our analysis shows that the coverage for an HIV-1 vaccine targeting sequences surrounding all 12 PCSs, 5 PCSs in Gag or 6 PCSs in Pol can cover ~ 70% to ~ 100% of the populations analyzed. There was no statistical difference in population coverages for the majority of populations examined when comparing the CD8 T cell epitope sets (12-PCSs, Gag-PCSs, and Pol-PCSs). As expected, vaccines targeting more sequences will have more CD8 T cell epitopes, as the mean average epitope hit for the 12-PCSs, Gag-PCSs, and Pol-PCSs across all countries studied was 9.45, 4.76, and 4.74, respectively, and across all geographical regions was 9.76, 4.99, and 4.92, respectively. The average PC90 for the 12-PCSs, Gag-PCSs, and Pol-PCSs across all countries studied was 2.53, 1.31, and 1.41, respectively, and across all geographical regions was 2.24, 1.23, and 1.29, respectively. Thus, vaccines targeting sequences surrounding the HIV-1 PCSs can cover broad populations; however, whether targeting a subset of the PCSs is sufficient to prevent acquisition requires further preclinical investigation.
- Published
- 2021
- Full Text
- View/download PDF